Transplant Genomics has appointed Nicholas Grund as President, John Slaught as vice president of sales, and Charles Argentine as director of clinical operations.
Grund will be responsible for developing and implementing new strategies to grow Transplant Genomics' existing business, expanding the company's TruGraf portfolio into new organ types, and working with customers, advocates, and payors to establish long term relationships. He will head company initiatives to increase TruGraf usage in the community-based nephrology market, and will also shepherd the launch of TruGraf Liver in the second half of 2021.
Grund has more than 25 years of commercial leadership experience in the biopharmaceutical industry, including several global executive roles in finance, sales, and marketing. He previously served as chief commercial officer at AMAG Pharmaceuticals, and also spent 13 years at Sanofi, most recently as the leader of the company's rare disease and multiple sclerosis franchises in the Asia Pacific region and Canada.
Slaught has more than 25 years of commercial team leadership. He most recently served as VP of sales for Optum.
Argentine has more than 15 years of laboratory management experience, primarily in the areas of genetic sequencing and immunology. He most recently served as director of clinical laboratory operations at Roche Sequencing Solutions.